Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.46 -0.40 (-0.93%)
Streaming Delayed Price Updated: 3:32 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
Price Over Earnings Overview: Exelixis
Via Benzinga
Exploring Exelixis's Earnings Expectations
Via Benzinga
Is the Market Bullish or Bearish on Exelixis?
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – An Undervalued Biotech Stock with Strong Fundamentals
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers. 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High Growth Momentum and Minervini’s Trend Template
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before... 
Via Chartmill
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Demystifying Exelixis: Insights From 8 Analyst Reviews
Via Benzinga
Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market. 
Via Benzinga
Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge. 
Via Benzinga
Why Exelixis Stock Is Skyrocketing Today
Via The Motley Fool
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628. 
Via Benzinga
Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations
The top-notch biotech company easily beat first-quarter profit expectations. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Earnings Scheduled For May 13, 2025
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate 
Via Chartmill
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Exelixis, Inc.
Via Business Wire
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy?
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock. 
Via Chartmill
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL). 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout. 
Via Chartmill
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.